ProgramsView all programs
From the news
- Chancellor Amma Addresses the Parliament of World’s Religions
- Amrita Students Qualify for the European Mars Rover Challenge
Publication Type : Journal Article
Thematic Areas : Nanosciences and Molecular Medicine
Publisher : Journal of Biomedical Nanotechnology
Source : Journal of Biomedical Nanotechnology, Volume 10, Number 4, p.559-570 (2014)
Keywords : Animals, apoptosis, article, Assays, Biochemistry, biodegradable, cancer therapy, Cell death, Cell Line, cell migration assay, Cell Survival, cell viability, Cercopithecus aethiops, controlled study, Copolymers, Diffusion, Diseases, drug, drug efficacy, Emulsification, encapsulation, evaporation, Flavonoids, flow cytometry, Hemolysis, human, human cell, Humans, in vitro study, infrared spectroscopy, L-lactic-co-glycolic acid), Lactic acid, light scattering, male, metabolic clearance rate, Nanocapsules, nanoencapsulation, Nanoparticles, Oncology, Poly(D, polyglactin, polyglycolic acid, prospective study, prostate cancer, Prostate cancers, Prostatic Neoplasms, scanning electron microscopy, Silymarin, slow release formulation, sustained drug release, tissue distribution, treatment outcome, Tumor, Vero cells
Campus : Kochi
School : Center for Nanosciences
Center : Amrita Center for Nanosciences and Molecular Medicine Move, Nanosciences
Department : Nanosciences and Molecular Medicine
Year : 2014
Abstract : Silymarin, a clinically proved hepato-protective herbal drug having significant anti-cancerous property towards prostate cancer, is inadequately utilized for cancer therapy due to its hydrophobic nature and poor bioavailability. In this work, we have developed silymarin Poly(D,L-lactic-co- glycolic acid) (PLGA) nanoparticles (NPs) in order to improve the therapeutic efficacy of silymarin towards prostate cancer by single emulsion solvent evaporation technique. The prepared nanoparticles had an encapsulation efficiency of 60% and a loading efficiency of 13%. The silymarin-PLGA NPs (SNPs) characterization, using DLS and SEM analysis revealed its size as less than 300 nm. FT-IR analysis confirmed encapsulation of silymarin by the SNPs, whereas XRD and TGA proved amorphous nature of the SNPs. In vitro drug release study demonstrated a slow and sustained release of encapsulated drug from the SNPs in physiological conditions. The hemocompatibility of the SNPs was established by in vitro hemolysis and coagulation assays. In vitro cell viability studies revealed preferential toxicity of SNPs towards prostate cancer cells (PC-3) compared to normal cells (Vero) in a dose dependant way. Cell uptake studies using confocal microscopy confirmed internalization of the SNPs by PC-3 cells. Furthermore, in vitro cell migration assay showed a concentration and time dependent inhibitory effect of SNPs on PC-3 cell migration. Finally, flow-cytometry based apoptosis assay suggested induction of apoptosis mediated death in PC-3 cells by the SNPs. Overall, the prepared SNPs proved as a promising candidate for prostate cancer therapy.
Cite this Research Publication : K. S. Snima, Arunkumar, P., Dr. Jayakumar Rangasamy, and Lakshmanan, V. - K., “Silymarin Encapsulated Poly(D,L-lactic-co-glycolic acid) Nanoparticles: A Prospective Candidate for Prostate Cancer Therapy”, Journal of Biomedical Nanotechnology, vol. 10, pp. 559-570, 2014.